PRO-SCT SIGNED
PROducing Stem Cells for improved Treatment of patients
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0PRO-SCT project word cloud
Explore the words cloud of the PRO-SCT project. It provides you a very rough idea of what is the project "PRO-SCT" about.
Project "PRO-SCT" data sheet
The following table provides information about the project.
| Coordinator |
CELL2CURE APS
Organization address contact info |
| Coordinator Country | Denmark [DK] |
| Project website | https://cell2cure.com/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-06-01 to 2019-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CELL2CURE APS | DK (BIRKEROD) | coordinator | 50˙000.00 |
Map
Project objective
The market for stem cells is growing fast as new possibilities for stem cell treatments evolve. Today stem cell treatments are often based on a process where the patient’s own cells are grown for weeks, and thereafter patients are treated with their own stem cells. This process limits a wider use of these treatments, as it is a slow and costly procedure. The key novelty in the PRO-SCT project is that it is the first fully compliant industrially applicable platform capable of large-scale stem cell production from healthy donor adipose tissue, making ready-to-use stem cells available whenever and wherever needed. Cell2Cure has leading competencies in the areas of producing, storing, and distributing stem cells from donors, and clinical and regulatory know-how in the use of cell-based therapies. C2C stem cells will be manufactured in large batches, stored frozen in vials that can be ready for use in a few minutes before treatment. The C2C technology uses state-of-the-art automated closed bioreactor systems with animal component free expansion of allogeneic cells and long-term cryopreservation of ready-to-use vials. Compared to today's stem cell treatment, this allows for scalability and easy distribution - improving availability and reducing both cost and time to treatment. With a strong scientific basis, Cell2Cure has made significant progress in the understanding of donor derived stem cells in the development of treatments for heart failure. Clinical trials have shown that C2C stem cells are safe, usable and have promising clinical effects. The aim of the PRO-SCT project is to develop a strong commercial and operational position for Cell2Cure to move from small scale to large scale capacity and unlock a new global market for adipose tissue derived donor stem cells. To do this successfully, the support of EU-Instrument phase I will be of immense importance. Cell2Cure has firm control of the intellectual property with a broadly covering WO-patent application in place.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRO-SCT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PRO-SCT" are provided by the European Opendata Portal: CORDIS opendata.